GlassScriptPhysician profile
Rimsha Hasan
NPI 1225418445
$5,382.67
in general payments reported to CMS, 2019-2025
31 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,924 · 2020: $221 · 2021: $249 · 2022: $1,309 · 2023: $470 · 2024: $793 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,432.05 | 2019-2022 | |
| Boston Scientific Corporation | $839.12 | 2019-2025 | Ekosonic, Eluvia, General - Angiography |
| Novartis Pharmaceuticals Corporation | $648.72 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $504.39 | 2022 | |
| Shockwave Medical, INC | $225.11 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $220.51 | 2022-2025 | |
| Medtronic Vascular, INC. | $199.20 | 2019 | |
| Medtronic, INC. | $125.97 | 2022-2025 | Symplicity G3, Telescope, In.Pact Admiral |
| E.R. Squibb & Sons, L.L.C. | $117.73 | 2022-2025 | Camzyos, Eliquis |
| Cardiovascular Systems INC. | $108.69 | 2020-2023 | Diamondback Coronary |
| Janssen Pharmaceuticals, INC | $107.49 | 2021-2023 | Xarelto |
| Amgen INC. | $106.90 | 2021-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $106.63 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.94 | 2020-2022 | |
| Astellas Pharma US INC | $99.00 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.58 | 2020-2024 | Lifevest |
| Baxter Healthcare | $42.55 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Abiomed | $35.35 | 2022-2023 | Impella |
| Angiodynamics, INC. | $31.46 | 2025 | Alphavac |
| Actelion Pharmaceuticals US, INC. | $28.39 | 2024 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $28.31 | 2019 | |
| Esperion Therapeutics, INC. | $27.51 | 2022-2023 | Nexletol |
| Cashflow Solutions, LLC | $23.86 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Lexicon Pharmaceuticals, INC. | $21.91 | 2024 | |
| Cordis US Corp. | $18.82 | 2022 | |
| Merck Sharp & Dohme LLC | $17.48 | 2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $17.07 | 2021 | |
| Philips North America LLC | $17.06 | 2025 | Extended Holter |
| Bridgebio Pharma, INC. | $16.65 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $16.25 | 2021 | |
| Novo Nordisk INC | $15.97 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rimsha Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.